ES2069295T3 - Acidos dihidrobenzopiran-2-carboxilicos substituidos con alcoxi y derivados de los mismos. - Google Patents
Acidos dihidrobenzopiran-2-carboxilicos substituidos con alcoxi y derivados de los mismos.Info
- Publication number
- ES2069295T3 ES2069295T3 ES91910026T ES91910026T ES2069295T3 ES 2069295 T3 ES2069295 T3 ES 2069295T3 ES 91910026 T ES91910026 T ES 91910026T ES 91910026 T ES91910026 T ES 91910026T ES 2069295 T3 ES2069295 T3 ES 2069295T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- dihidrobenzopiran
- alcoxy
- derivatives
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
ESTA INVENCION ESTA RELACIONADA CON LOS COMPUESTOS DE LA FORMULA (I) Y LOS ESTEROISOMEROS Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, EN DONDE R ES ALQUILO, ALQUENILO, ALQUINILO O (CH2)MR3 EN DONDE R3 ES CICLOALQUILO Y M TIENE EL VALOR DE 1 O 2; R1 ES ALQUILO; R2 ES HIDROGENO O ALQUILO; R4 ES ALQUILO; N ES UN ENTERO DEL 1 AL 5; P ES UN ENTERO DEL 0 AL 6; Y ES NH, OXIGENO O AZUFRE; Y Z ES HIDROGENO, ALQUILO, ALCOXI, NR4R5 EN DONDE R4 Y R5 SON, INDEPENDIENTEMENTE, HIDROGENO O ALQUILO, O SR6 EN DONDE R6 ES HIDROGENO, BENCILO O ALQUILO. LOS COMPUESTOS CON LA FORMULA (I) SON ANTAGONISTAS DEL LEUCOTRIENO B4 Y SON UTILES COMO AGENTES ANTIINFLAMATORIOS Y EN EL TRATAMIENTO DE LOS ESTADOS MEDIADOS POR EL LEUCOTRIENO B4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/521,777 US5073562A (en) | 1990-05-10 | 1990-05-10 | Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2069295T3 true ES2069295T3 (es) | 1995-05-01 |
Family
ID=24078110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES91910026T Expired - Lifetime ES2069295T3 (es) | 1990-05-10 | 1991-05-01 | Acidos dihidrobenzopiran-2-carboxilicos substituidos con alcoxi y derivados de los mismos. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5073562A (es) |
| EP (1) | EP0527922B1 (es) |
| JP (1) | JPH05507084A (es) |
| AT (1) | ATE119528T1 (es) |
| AU (1) | AU647487B2 (es) |
| CA (1) | CA2082500A1 (es) |
| DE (1) | DE69108025T2 (es) |
| DK (1) | DK0527922T3 (es) |
| ES (1) | ES2069295T3 (es) |
| GR (1) | GR3015349T3 (es) |
| IE (1) | IE62719B1 (es) |
| IL (1) | IL98090A (es) |
| NZ (1) | NZ238092A (es) |
| PT (1) | PT97614A (es) |
| WO (1) | WO1991017160A1 (es) |
| ZA (1) | ZA913546B (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2677021B1 (fr) * | 1991-05-31 | 1993-10-01 | Upsa Laboratoires | Nouveaux derives de thiazole antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant. |
| US5352690A (en) * | 1992-07-01 | 1994-10-04 | Eli Lilly And Company | 1,2,4-trioxygenated benzene derivatives useful as leukotriene antagonists |
| WO1995032201A1 (en) * | 1994-05-25 | 1995-11-30 | G.D. Searle & Co. | Alkoxy-substituted dihydrobenzopyran-2-sulfonimides derivatives, their preparation and their use as leukotriene b4 antagonists |
| US5516917A (en) * | 1994-06-08 | 1996-05-14 | G. D. Searle & Co. | Leukotriene B4 antagonists |
| US6051601A (en) * | 1994-10-13 | 2000-04-18 | Pfizer Inc. | Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4 (LTB4) antagonists |
| MX9702734A (es) * | 1994-10-13 | 1997-06-28 | Pfizer | Benzopirano y compuestos benzocondensados, su preparacion y su uso como antagonistas de leucotrieno b4 (ltb4). |
| JP2002528533A (ja) * | 1998-10-29 | 2002-09-03 | ブリストル−マイヤーズ スクイブ カンパニー | 酵素ｉｍｐｄｈの新規なインヒビター |
| AU9287401A (en) | 2000-09-27 | 2002-04-08 | Merck & Co Inc | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| JP4350946B2 (ja) * | 2000-10-31 | 2009-10-28 | メルク エンド カムパニー インコーポレーテッド | 糖尿病及び脂質異常症の治療のためのベンゾピランカルボン酸誘導体 |
| TWI256952B (en) * | 2003-08-27 | 2006-06-21 | Sk Corp | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| EP3257949A1 (en) | 2005-06-15 | 2017-12-20 | Complete Genomics Inc. | Nucleic acid analysis by random mixtures of non-overlapping fragments |
| EP2546360A1 (en) | 2005-10-07 | 2013-01-16 | Callida Genomics, Inc. | Self-assembled single molecule arrays and uses thereof |
| EP2495337A1 (en) | 2006-02-24 | 2012-09-05 | Callida Genomics, Inc. | High throughput genome sequencing on DNA arrays |
| JP2014531908A (ja) | 2011-10-14 | 2014-12-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 構造アッセンブリによる配列決定 |
| WO2013184754A2 (en) | 2012-06-05 | 2013-12-12 | President And Fellows Of Harvard College | Spatial sequencing of nucleic acids using dna origami probes |
| US9476089B2 (en) | 2012-10-18 | 2016-10-25 | President And Fellows Of Harvard College | Methods of making oligonucleotide probes |
| US9540685B2 (en) | 2013-03-15 | 2017-01-10 | President And Fellows Of Harvard College | Methods of identifying homologous genes using FISH |
| US20180320226A1 (en) | 2014-08-19 | 2018-11-08 | President And Fellows Of Harvard College | RNA-Guided Systems For Probing And Mapping Of Nucleic Acids |
| CN120700116A (zh) | 2019-10-18 | 2025-09-26 | 小利兰·斯坦福大学董事会 | 临床和工业规模的完整组织测序 |
| US12071667B2 (en) | 2020-11-04 | 2024-08-27 | 10X Genomics, Inc. | Sequence analysis using meta-stable nucleic acid molecules |
| US12060603B2 (en) | 2021-01-19 | 2024-08-13 | 10X Genomics, Inc. | Methods for internally controlled in situ assays using padlock probes |
| CN117396613A (zh) | 2021-06-01 | 2024-01-12 | 10X基因组学有限公司 | 用于分析物检测和探针解析的方法和组合物 |
| WO2022256422A1 (en) | 2021-06-02 | 2022-12-08 | 10X Genomics, Inc. | Sample analysis using asymmetric circularizable probes |
| WO2023288225A1 (en) | 2021-07-13 | 2023-01-19 | 10X Genomics, Inc. | Methods for preparing polymerized matrix with controllable thickness |
| CA3224093A1 (en) | 2021-07-30 | 2023-02-02 | Jorge Ivan Hernandez Neuta | Methods and compositions for synchronizing reactions in situ |
| US12139751B2 (en) | 2021-07-30 | 2024-11-12 | 10X Genomics, Inc. | Circularizable probes for in situ analysis |
| US12391984B2 (en) | 2021-08-03 | 2025-08-19 | 10X Genomics, Inc. | Compositions and methods for rolling circle amplification |
| CN118043476A (zh) | 2021-08-03 | 2024-05-14 | 10X基因组学有限公司 | 核酸多联体及其稳定和/或压缩方法 |
| US12460251B2 (en) | 2021-08-03 | 2025-11-04 | 10X Genomics, Inc. | Stabilization and/or compaction of nucleic acid molecules |
| EP4326898B1 (en) | 2021-08-16 | 2024-07-31 | 10X Genomics, Inc. | Probes comprising a split barcode region and methods of use |
| WO2023129898A2 (en) | 2021-12-27 | 2023-07-06 | 10X Genomics, Inc. | Methods and compositions for rolling circle amplification |
| EP4466376A1 (en) | 2022-01-21 | 2024-11-27 | 10X Genomics, Inc. | Multiple readout signals for analyzing a sample |
| US20240254537A1 (en) | 2022-02-23 | 2024-08-01 | Insitro, Inc. | Pooled optical screening and transcriptional measurements of cells comprising barcoded genetic perturbations |
| US20240026427A1 (en) | 2022-05-06 | 2024-01-25 | 10X Genomics, Inc. | Methods and compositions for in situ analysis of v(d)j sequences |
| US20240035071A1 (en) | 2022-06-17 | 2024-02-01 | 10X Genomics, Inc. | Catalytic de-crosslinking of samples for in situ analysis |
| EP4602344A1 (en) | 2022-10-14 | 2025-08-20 | 10X Genomics, Inc. | Methods for analysis of biological samples |
| US20240167081A1 (en) | 2022-11-08 | 2024-05-23 | 10X Genomics,Inc. | Immobilization methods and compositions for in situ detection |
| WO2024107887A1 (en) | 2022-11-16 | 2024-05-23 | 10X Genomics, Inc. | Methods and compositions for assessing performance of in situ assays |
| US20240218437A1 (en) | 2022-12-16 | 2024-07-04 | 10X Genomics, Inc. | Methods and compositions for assessing performance |
| US20240263219A1 (en) | 2023-01-06 | 2024-08-08 | 10X Genomics, Inc. | Methods and compositions for in situ analysis of variant sequences |
| EP4658813A2 (en) | 2023-02-03 | 2025-12-10 | 10X Genomics, Inc. | In situ analysis of variant sequences in biological samples |
| WO2025029831A1 (en) | 2023-07-31 | 2025-02-06 | 10X Genomics, Inc. | Methods and systems for targeted rna cleavage and target rna-primed rolling circle amplification |
| US20250207203A1 (en) | 2023-12-20 | 2025-06-26 | 10X Genomics, Inc. | In situ detection of copy number variations in biological samples |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1384530A (en) * | 1971-07-29 | 1975-02-19 | Fisons Ltd | Chromone derivatives |
| ATE14579T1 (de) * | 1979-03-20 | 1985-08-15 | Fisons Plc | Pharmazeutische heterocyclische verbindungen, verfahren zu ihrer herstellung und sie enthaltende zusammensetzungen. |
| EP0079637B1 (en) * | 1981-11-12 | 1987-01-28 | FISONS plc | Anti-srs-a carboxylic acid derivatives, processes for their production, and pharmaceutical formulation containing them |
| ZA844519B (en) * | 1983-06-24 | 1985-02-27 | Hoffmann La Roche | Dihydrobenzopyran derivatives |
| US4788214A (en) * | 1983-06-24 | 1988-11-29 | Hoffman-La Roche Inc. | 3,4-dihydro-2H-1-benzopyran derivatives |
| ZA84345B (en) * | 1983-08-08 | 1985-02-27 | Searle & Co | Substituted dihydrobenzopyrans |
| US4665203A (en) * | 1983-08-08 | 1987-05-12 | G. D. Searle & Co. | Substituted dihydrobenzopyrans useful as leukotriene D4 inhibitors |
| US4778903A (en) * | 1983-12-12 | 1988-10-18 | G. D. Searle & Co. | Substituted dihydrobenzopyrans |
| US4565882A (en) * | 1984-01-06 | 1986-01-21 | G. D. Searle & Co. | Substituted dihydrobenzopyran-2-carboxylates |
| US4546194A (en) * | 1984-05-29 | 1985-10-08 | G. D. Searle & Co. | Substituted chromanon-2-yl alkanols and derivatives thereof |
| US4889871A (en) * | 1987-05-29 | 1989-12-26 | G. D. Searle & Co. | Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives |
| MX13485A (es) * | 1987-10-19 | 1993-05-01 | Pfizer | Procedimiento para obtener tetralinas, cromados y compuestos relacionados, sustituidos |
-
1990
- 1990-05-10 US US07/521,777 patent/US5073562A/en not_active Expired - Fee Related
-
1991
- 1991-05-01 EP EP91910026A patent/EP0527922B1/en not_active Expired - Lifetime
- 1991-05-01 JP JP91509388A patent/JPH05507084A/ja active Pending
- 1991-05-01 AU AU79020/91A patent/AU647487B2/en not_active Ceased
- 1991-05-01 ES ES91910026T patent/ES2069295T3/es not_active Expired - Lifetime
- 1991-05-01 DE DE69108025T patent/DE69108025T2/de not_active Expired - Fee Related
- 1991-05-01 WO PCT/US1991/002981 patent/WO1991017160A1/en not_active Ceased
- 1991-05-01 DK DK91910026.3T patent/DK0527922T3/da active
- 1991-05-01 CA CA002082500A patent/CA2082500A1/en not_active Abandoned
- 1991-05-01 AT AT91910026T patent/ATE119528T1/de not_active IP Right Cessation
- 1991-05-09 IL IL9809091A patent/IL98090A/en not_active IP Right Cessation
- 1991-05-09 PT PT97614A patent/PT97614A/pt not_active Application Discontinuation
- 1991-05-09 NZ NZ238092A patent/NZ238092A/xx unknown
- 1991-05-09 IE IE158391A patent/IE62719B1/en not_active IP Right Cessation
- 1991-05-10 ZA ZA913546A patent/ZA913546B/xx unknown
-
1995
- 1995-03-09 GR GR950400438T patent/GR3015349T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK0527922T3 (da) | 1995-05-22 |
| JPH05507084A (ja) | 1993-10-14 |
| CA2082500A1 (en) | 1991-11-11 |
| IL98090A (en) | 1995-07-31 |
| GR3015349T3 (en) | 1995-06-30 |
| EP0527922B1 (en) | 1995-03-08 |
| DE69108025T2 (de) | 1995-08-10 |
| IE911583A1 (en) | 1991-11-20 |
| IL98090A0 (en) | 1992-06-21 |
| NZ238092A (en) | 1993-10-26 |
| ZA913546B (en) | 1992-07-29 |
| AU647487B2 (en) | 1994-03-24 |
| ATE119528T1 (de) | 1995-03-15 |
| DE69108025D1 (de) | 1995-04-13 |
| US5073562A (en) | 1991-12-17 |
| WO1991017160A1 (en) | 1991-11-14 |
| EP0527922A1 (en) | 1993-02-24 |
| AU7902091A (en) | 1991-11-27 |
| IE62719B1 (en) | 1995-02-22 |
| PT97614A (pt) | 1992-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2069295T3 (es) | Acidos dihidrobenzopiran-2-carboxilicos substituidos con alcoxi y derivados de los mismos. | |
| ES2080334T3 (es) | Antagonistas de leucotrieno b4. | |
| ES520300A0 (es) | Procedimiento para la obtencion de 1,4-dihidropiridinas. | |
| ES2070186T3 (es) | Nuevos derivados de 2,4-diamino-pirimidina-3-oxido y su utilizacion en la prevencion de la caida de los cabellos. | |
| FI960155A7 (fi) | Terapeuttisia heterosyklisiä yhdisteitä | |
| DK1224940T4 (da) | Flydende formuleringer af interferon-beta | |
| DK307289D0 (da) | Pyrimidinderivater | |
| DK359387A (da) | Oploesninger af oxazaphosphoriner med forbedret stabilitet og fremgangsmaade til deres fremstilling | |
| ES2116290T3 (es) | 2(5h)-furanonas sustituidas en posicion 3, como antagonistas del canal del ca2+ y agentes anti-inflamatorios. | |
| DE68916847D1 (de) | Monopersulfate von Amino-(poly)percarbonsäuren. | |
| FI910303A0 (fi) | Derivat av tiazolidin med blodtrycksnedsaenkande effekt och terapeutisk anvaendning av dessa. | |
| ES2062792T3 (es) | Acidos dihidrobenzopiran-2-carboxilicos alcoxi-sustituidos y derivados de los mismos. | |
| ES2070623T3 (es) | Oxisulfonilureas inhibidoras de acat. | |
| PH22424A (en) | (1-arylcyclobutly)-(heterocyclyl)-methylamine compounds useful as therapeutic agents | |
| NO904187D0 (no) | Benzanilider. | |
| ATE127451T1 (de) | 3,4-disubstituierte phenyl-heterocyclen und deren verwendung. | |
| DE59206593D1 (de) | Verwendung von 2-Iminothiazolidin-4-onderivaten als neuartige Arzneimittelwirkstoffe | |
| ES2037783T3 (es) | Procedimiento para la obtencion de 3-aminosidnoniminas substituidas. | |
| SE8400629L (sv) | Basiska oximetrar | |
| DE68901085D1 (de) | Verwendung von substituierten benzamiden zur stimulierung der gastromotorik. | |
| FI870067A0 (fi) | Metionin-substituerade 1,4-dihydropyridiner, foerfarande foer deras framstaellning och deras anvaendning. | |
| PT92175A (pt) | Processo para a preparacao de 3-amino-sidnoniminas substituidas e de produtos intermediarios farmacologicamente activos | |
| SE8802162D0 (sv) | Nya aminoacylater av glycerolacetal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 527922 Country of ref document: ES |